Transforaminal Epidural Injection in Acute Sciatica

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorC.L.A.Vleggeert-Lankamp

About this trial

Patients suffering from sciatica are treated conservatively for the first 8 weeks due to the favourable prognosis. This period is preferably extended up to 14-16 weeks after which patients may opt for surgery. However, patients may experience severe discomfort due to pain in the leg which can lead to decreased physical activity and socio-economic problems. An adequate therapy to alleviate symptoms during this period of 'wait-and-see' is lacking. In this study, patients will be randomized to treatment with transforaminal epidural injections or standard oral pain medication.

Eligibility criteria

Qualifiers

Diagnosed with sciatica by GP

NRS leg pain of 6 or more on a 10-point NRS scale

Minimum duration of symptoms of 3 weeks and maximum duration of 8 weeks

Disqualifiers

Age under 18 years

Condition preventing to receive transforaminal epidural injection

Severe scoliosis

Transforaminal epidural injection received in 6 months before randomization date

Trial design

Treatments tested in this trial

  • Lidocaine
  • Methylprednisolone Acetate
  • Dexamethasone

Treatment groups

142 Participants
are divided into 2 treatment groups

Sponsors and collaborators

C.L.A.Vleggeert-Lankamp

Lead sponsor

Leiden University Medical Center

Sponsor institution

Spaarne Gasthuis

Collaborator

Stichting Achmea Gezondheidszor

Collaborator

Posthumus Meyjes Fonds

Collaborator